An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

Objectives CpG ODN is a Toll-like receptor 9 agonist with immunotherapeutic potential for many cancer types, including aggressive breast cancers. There is strong interest in utilizing CpG ODN as an adjuvant to improve clinical efficacy of current treatments and immunogenicity of breast cancers not t...

Full description

Bibliographic Details

Published in:	Cancer Control
Main Authors:	Dionisia Quiroga DO, PhD, Robert Wesolowski MD, Sara Zelinskas BS, Ashley Pinette MD, Brooke Benner PhD, Emily Schwarz BS, Himanshu Savardekar BS, Courtney Johnson DO, Andrew Stiff MD, PhD, Lianbo Yu PhD, Erin Macrae MD, Maryam Lustberg MD, MPH, Ewa Mrozek MD, Bhuvaneswari Ramaswamy MD, William E. Carson MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-04-01
Online Access:	https://doi.org/10.1177/10732748241250189